Last reviewed · How we verify
NCT05894252
Walking Interventions to Improve Quality of Life Among Adults with T2D in SA and the UK
NA trial testing Walking Interventions in Type 2 Diabetes in 103 participants. Completed in 20 March 2024.
20 March 2024
Quick facts
| Lead sponsor | University of Reading |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 103 |
| Start date | 14 June 2023 |
| Primary completion | 20 March 2024 |
| Estimated completion | 20 March 2024 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Walking Interventions
Conditions studied
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
- Quality of Life — all drugs for Quality of Life →
Sponsor
University of Reading
Who can join
Adults 18 to 64, any sex, with Type 2 Diabetes or Quality of Life. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The research will be conducted as a quantitative experimental study (as an intervention). For the primary DV, quality of life, there are two effective measures. * Health-related Quality of Life (HRQoL) scales of the SF-36 short form * Euro-QoL instruments (EQ-5D). Additionally, secondary variables assessed will be: * (Physical Activity (the International PA questionnaire, short form - IPAQ) * General Anxiety (the Generalised Anxiety Disorder Assessment - GAD-7 * Symptoms of Depression (the Patient Health Questionnaire - PHQ-9) * Habitual diet will be assessed with the EPIC food frequency questionnaire, * Memory function through the Gorilla online questionnaire (Memory Intrusion - TB1 and TB2). * Health locus of control (Multidimensional Health Locus of Control form C) Participants in the intervention group will be required to complete a 30-minute walk five days a week for 12 weeks. This will be in addition to any regular walking or exercise they are currently doing, which will be assessed via questionnaire at baseline. In the control group, participants will be asked to continue with their daily routines and usual level of physical activity. The baseline measurements will be taken before the intervention at week zero. Subsequently, all the participants will attend a virtual meeting (screening visit) to learn about the key aspects of the research, including the required actions of the control and intervention groups, how to use the act watch and report the required data. All participants in the intervention group and the control group will be required to wear acti-watches, which will be given to them for free. Participants in both groups will be asked to report the number of steps covered each week. Participants will report this information through an online link provided by the researcher. Each participant will access their data through an app that comes with the watch, however, the researchers will not have access to the app
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05894252
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 2 Diabetes
Currently open trials in the same condition.
- NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
- NCT07254689 — The Food for Health Study · NA · recruiting
- NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting
Other University of Reading trials
Trials by the same sponsor.
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07401212 — GUTLINK4KIDS Intervention · NA · recruiting
- NCT07006909 — Hair Isotope Analysis for Early Cancer Detection · not yet recruiting
- NCT06832488 — Food Texture, Eating Rate and Food Intake in Care Home Older Adults. · NA · completed
- NCT07056634 — The Effects of Nature-Based Activity vs. Indoor Exercise on Cognition, Psychological, and Physiological Health · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05894252 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Reading
- Last refreshed: 21 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05894252.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing